Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 1 天前评分70
正文 · 机器翻译
在既往 Al/CDK4/6i 治疗后疾病进展的情况下，总生存期在数值上倾向于 abemaciclib + fulvestrant；中位数为 32.1 vs 24.6 个月
HR 0.80, 95% CI 0.60-1.06) @KalinskyKevin @OncoAlert #ESMO26
118 浏览 · 4 赞 · 4 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgAssociation of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE
https://esmocongress.esmo.org来源：Stephanie Graff, MD, FACP, FASCO · x.com